Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:2793-2801
Published online before print November 19, 2007, doi: 10.1161/CIRCULATIONAHA.107.694273
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
116/24/2793    most recent
CIRCULATIONAHA.107.694273v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spencer, F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spencer, F. A.
Related Collections
Right arrow Acute myocardial infarction

(Circulation. 2007;116:2793-2801.)
© 2007 American Heart Association, Inc.


Health Services and Outcomes Research

Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction?

Frederick A. Spencer, MD; Mauro Moscucci, MD; Christopher B. Granger, MD; Joel M. Gore, MD; Robert J. Goldberg, PhD; Philippe Gabriel Steg, MD; Shaun G. Goodman, MD; Andrzej Budaj, MD, PhD; Gordon FitzGerald, PhD; Keith A.A. Fox, MB, ChB, FRCP, for the GRACE Investigators

From McMaster University, Hamilton, Canada (F.A.S.); University of Massachusetts Medical School, Worcester (F.A.S., J.M.G., R.J.G., G.F.); Cardiovascular Center, University of Michigan, Ann Arbor (M.M.); Duke University Medical Center, Durham, NC (C.B.G.); Hôpital Bichat-Claude Bernard, Paris, France (P.G.S.); Terrence Donnelly Heart Centre, St Michael’s Hospital, University of Toronto, and Canadian Heart Research Centre, Toronto, Ontario, Canada (S.G.G.); Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland (A.B.); and Cardiovascular Research, University of Edinburgh, Edinburgh, Scotland (K.A.A.F.).

Correspondence to Dr Frederick A. Spencer, Department of Medicine, McMaster University, Faculty of Health Sciences, 1200 Main St W, Hamilton, Canada, L8N 3Z5. E-mail fspence{at}mcmaster.ca

Received February 5, 2007; accepted October 2, 2007.

Background— Analyses from randomized controlled trials suggest that bleeding in patients with acute myocardial infarction is associated with poor outcomes. Because these data are not generalizable to all patients with acute myocardial infarction, we sought to better understand the scope of this problem in a "real-world" setting.

Methods and Results— We examined the frequency of major bleeding in 40 087 patients with acute myocardial infarction enrolled in the Global Registry of Acute Coronary Events. Regression analyses were used to examine the association between patient and treatment characteristics, bleeding, and hospital and postdischarge outcomes. Major bleeding occurred in 2.8% of patients. These patients were older, more severely ill, and more likely to undergo invasive procedures. Patients with bleeding were more likely to die during hospitalization (hazard ratio, 1.9; 95% confidence interval, 1.6 to 2.2) but not after discharge (hazard ratio, 0.8; 95% confidence interval, 0.6 to 1.0) than patients who did not bleed. Continuation of antithrombotic therapies after day 1 was lower in patients who experienced early bleeding. Moreover, in patients who bled, hospital mortality was increased in those who discontinued aspirin, thienopyridines, or low–molecular-weight heparins.

Conclusions— Major bleeding occurred in 1 in 35 patients with acute myocardial infarction; these patients accounted for {approx}10% of all hospital deaths. Nevertheless, risk of hospital mortality associated with bleeding was much lower than reported in randomized controlled trials. These data suggest that although bleeding may be causally related to adverse outcomes in some patients in the real-world setting, it is often merely a marker for patients at higher risk for adverse outcomes.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
NEJMHome page
D. A. Morrow
Antithrombotic Therapy to Support Primary PCI
N. Engl. J. Med., May 22, 2008; 358(21): 2280 - 2282.
[Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
What Is the Impact of Bleeding After Acute MI Treatment?
Journal Watch Cardiology, February 6, 2008; 2008(206): 3 - 3.
[Full Text]


Home page
CirculationHome page
P. B. Berger and S. V. Manoukian
Bleeding Is Bad.... Isn't It?
Circulation, December 11, 2007; 116(24): 2776 - 2778.
[Full Text] [PDF]